62nd ASH Annual Meeting and Exposition. Virtual. 5-8 diciembre, 2020

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.

Iván Martín, Eva Villamón, Rosario Abellán, Mª José Calasanz, Aroa Irigoyen, Guillermo Sanz, Esperanza Such, Elvira Mora, Míriam Gutiérrez, Rosa Collado, Míriam Vara, Mª Laura Blanco, Itziar Oiartzabal, Sara Álvarez, Teresa Bernal, Isabel Granada, Blanca Xicoy, Andrés Jerez, Raquel Fernández, Marisa Calabuig, Francisca García, Alejandro Sanz, Rosana Díez, Ángela Gil, Raquel de Paz, Francisca López, Teresa González, Carlos Solano and Mar Tormo. Spanish Group of Myelodysplastic Syndromes (GESMD). (Pendiente resolución)

Un Índice Pronóstico Internacional Revisado (Ips S-r) De 3.5 Puntos Estratifica A Los Pacientes Con Síndrome Mielodisplásico (Smd) En 2 Grupos De Riesgo

Montoro Maria Julia1, Ortega Margarita1, Villacampa Guillermo2, Bernal Teresa3, Pomares Helena4, Mora Elvira5, Molero Antonieta1, Vilorio Laura3, Tormo Mar6, Díaz-Beyá Marina7, Merchán Brayan8, Jerez Andrés9, Rivero Eugenia10, Lis Maria José11, Cárcel Paula12, Bargay Joan13, Ramos Fernando14, Xicoy Blanca15, Díez-Campelo María16, andValcárcel David1, with the collaboration of the Spanish Group of the Myelodysplastic Syndromes

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients – Interim Analysis of the European Sintra-REV Trial

Félix López Cadenas, MD , Eva Lumbreras , Blanca Xicoy, MD , Joaquín Sánchez, MD , Rosa Coll, MD , Bohrane Slama, MD , Jose Angel HernandezRivas, MD, PhD , Sylvain Thepot, MD , Teresa Bernal, MD, PhD , Beatriz Arrizabalaga, MD. PhD , Agnès Guerci-Bresler, MD, PhD , Guillermo F Sanz, MD, PhD , Joan Bargay, MD , Maria Luz Amigo, MD , Raquel de Paz, MD , Benet Nomdedeu, MD , Aristoteles Giagounidis , Uwe Platzbecker, MD ,Stefan Wickenhauser , Katharina S. Götze , Ali Arar , Jesus María Hernández Rivas, MD, PhD , Pierre Fenaux, MD, PhD , Consuelo Del Cañizo, MD,PhD and Maria Diez-Campelo, MD, PhD

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

David P. Steensm1, Martin Wermke, Virginia M. Klimek, Peter L Greenberg, Patricia Font, Rami S. Komrokji, Jay Yang, Andrew M. Brunner, Hetty E. Carraway, Lionel Ades, Aref Al-Kali Juan Manuel Alonso Dominguez, Ana Alonso, Catherine C. Coombs, H. Joachim Deeg, William B. Donnellan, James M. Foran, Guillermo Garcia-Manero, Michael B. Maris, Malgorzata McMasters, Jean-Baptiste Mico1, Jaime Perez De Oteyza, Felicitas Thol, Eunice S. Wang, Justin M. Watts, Silvia Buonamici, Amy Kim, Vikram Gourineni, Alyssa J Marino, Nathalie Rioux, Joanne Schindler, Sherri Smith, Huilan Yao, Xiaobin Yuan, Kun Yu, Uwe Platzbecker.